

lyuzeh™ (latanoprost) - New drug approval

- On December 14, 2022, <u>Thea Pharma announced</u> the FDA approval of <u>lyuzeh (latanoprost)</u>, for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Iyuzeh is the first preservative-free formulation of latanoprost. Other formulations of latanoprost are available under the brand name Xalatan® (generically available as well) and Xelpros®.
- In randomized, controlled clinical trials of patients with open angle glaucoma or ocular hypertension with mean baseline IOP of 19 to 24 mmHg, Iyuzeh lowered IOP by 3 to 8 mmHg vs. 4 to 8 mmHg by latanoprost ophthalmic solution preserved with benzalkonium chloride. Latanoprost ophthalmic solution preserved with benzalkonium chloride was approximately 1 mmHg more effective than Iyuzeh.
- Warnings and precautions for lyuzeh include pigmentation, eyelash changes, intraocular inflammation, macular edema, herpetic keratitis, and contact lens use.
- The most common adverse reactions (5% to 35%) with lyuzeh use were conjunctival hyperemia, eye irritation, eye pruritus, abnormal sensation in eye, foreign body sensation in eyes, vision blurred, and increased lacrimation.
- The recommended dosage of lyuzeh is one drop in the affected eye(s) once daily in the evening.
- Thea Pharma plans to launch lyuzeh in the second half of 2023. lyuzeh will be available as a 0.005% ophthalmic solution.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.